title: Antitumor effect of embryonic stem cells in a non-small cell lung cancer model: antitumor factors and immune responses.
abstract: Research in recent years has revealed that embryonic stem cells (ESCs) could generate obvious antitumor effects in both vitro and vivo. In vitro, ESCs could secrete soluble factors that are capable of blocking cancer cells proliferation, moreover, embryonic microenvironments could effectively inhibit tumorigenesis and metastasis; while in vivo, administration of ESCs in tumor-bearing mice could generate significant antitumor effects by indirectly activating the antitumor immune system. In this study, non-small cell lung cancer cells (Lewis Lung Carcinoma cells, LLCs) and ESCs were co-injected together into mice, after that subcutaneous tumor growth was monitored, cellular and humoral immune responses were detected, and different control groups were set to compare the results in different conditions. Our results suggested that compared to be injected alone, ESCs co-injected with cancer cells could inhibit cancer cell growth more efficiently in vivo, with more CD8+ lymphocytes generated in both peripheral circulation and spleen, and with higher serum anticancer cytokine level (interleukin (IL)-2 and interferon (IFN)-γ). We conclude that the boosted antitumor effects induced by ESCs and cancer cells co-injection may be both the effects of antitumor factors secreted by ESCs and immune responses induced by ESCs in vivo.
authors: Institute of Oncology, Shandong Provincial Hospital affiliated to Shandong University, Shandong University, 324 Jingwu Road, Jinan, 250021 P.R. China.
authors: Wei
authors: W
authors: Dong
authors: Chen
authors: C
authors: Qiu
authors: Hongchang
authors: H
authors: Shen
authors: Qi
authors: Q
authors: Liu
authors: Jiajun
authors: J
authors: Du
mesh_terms: D000818:Animals; D002289:Carcinoma, Non-Small-Cell Lung / Q000628:therapy*; D053595:Embryonic Stem Cells / Q000166:cytology / Q000502:physiology*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005434:Flow Cytometry; D007150:Immunohistochemistry; D007167:Immunotherapy; D020287:In Situ Nick-End Labeling; D007371:Interferon-gamma / Q000378:metabolism; D007376:Interleukin-2 / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL
chemical_list: D007376:Interleukin-2; D007371:Interferon-gamma
keywords: antitumor factors.; antitumor immunity; embryonic stem cells; immunotherapy
references: Nat Immunol. 2002 Nov;3(11):999-1005
references: 12407407
references: Proc Natl Acad Sci U S A. 2008 Mar 18;105(11):4329-34
references: 18334633
references: Eur J Pharmacol. 2008 Jun 24;588(1):9-17
references: 18455723
references: Cancer Chemother Rep 2. 1972 Nov;3(1):325-30
references: 4660735
references: Scand J Immunol. 2009 Dec;70(6):516-25
references: 19906192
references: Stem Cells. 2009 Dec;27(12):3103-11
references: 19816950
references: J Immunol. 2006 Feb 1;176(3):1999-2006
references: 16424232
references: Cell Prolif. 2009 Dec;42(6):788-98
references: 19732065
references: Stem Cells. 2006 Mar;24(3):501-5
references: 16293574
references: Stem Cells. 2011 Jan;29(1):11-9
references: 21280155
references: Semin Reprod Endocrinol. 1999;17(3):275-90
references: 10797946
references: Eur Arch Otorhinolaryngol. 2009 Feb;266(2):161-70
references: 18807062
references: Surgery. 2007 Apr;141(4):415-9
references: 17383517
references: Cancer Res. 2005 Apr 15;65(8):3035-9
references: 15833829
references: Leukemia. 2007 Feb;21(2):304-10
references: 17170725
references: Stem Cells. 2006 Feb;24(2):221-9
references: 16109762
references: Immunol Rev. 2006 Jun;211:214-24
references: 16824130
references: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references: 21296855
references: Cell Res. 2008 Apr;18(4):500-7
references: 18364678
references: Adv Drug Deliv Rev. 2005 Dec 12;57(13):1944-69
references: 16289432
references: J Immunol. 2010 Jul 15;185(2):998-1004
references: 20562261
references: Cancer Res. 1998 Aug 15;58(16):3660-7
references: 9721876
references: Cancer Chemother Pharmacol. 2008 Nov;62(6):959-63
references: 18259753
references: Biomaterials. 2011 Jun;32(17):4130-9
references: 21411140
references: Nat Rev Cancer. 2003 Dec;3(12):895-902
references: 14737120
references: Expert Rev Mol Diagn. 2009 Sep;9(6):545-54
references: 19732002
references: Int J Nanomedicine. 2011;6:1945-54
references: 21976971
references: Clin Cancer Res. 2008 Jul 15;14(14):4385-91
references: 18628452
references: Nature. 2005 Apr 14;434(7035):843-50
references: 15829953
references: Exp Mol Pathol. 2009 Jun;86(3):192-7
references: 19171137
references: J Am Assoc Lab Anim Sci. 2010 Mar;49(2):202-6
references: 20353696
references: Oncol Rep. 2009 Aug;22(2):337-43
references: 19578774
references: Cancer Immunol Immunother. 2010 Nov;59(11):1697-705
references: 20683592
references: Cell. 2010 Mar 19;140(6):883-99
references: 20303878
references: Cancer Res. 2006 May 1;66(9):4553-7
references: 16651403
references: Trends Immunol. 2004 Sep;25(9):465-70
references: 15324738
references: Int J Nanomedicine. 2010 Sep 07;5:593-9
references: 20856834
references: Int J Cancer. 2010 Jun 1;126(11):2622-34
references: 19824039
references: J Immunol. 2005 Mar 1;174(5):2591-601
references: 15728465